InvestorsHub Logo
Post# of 253279
Next 10
Followers 839
Posts 120532
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 203165

Saturday, 08/06/2016 12:26:43 PM

Saturday, August 06, 2016 12:26:43 PM

Post# of 253279
More musings on CHECKMATE-026 trial/NYT write-up:

http://www.nytimes.com/2016/08/06/business/lung-cancer-drug-opdivo-fails-clinical-trial-to-expand-use.html

Not a bad synopsis, but author Andrew Pollack could have gone further by saying that Opdivo and Keytruda are very similar drugs (not merely members of the same class), and hence there’s no credible thesis for why Opdivo wouldn’t work well in first-line NSCLC among patients with sufficiently high PD-L1 expression.

Further, I don’t expect the economic harm to BMY from CHECKMATE-026 to be nearly as large as Pollack implies. We may presume that MRK’s Keytruda will soon be approved for monotherapy in first-line NSCLC for patents with >=50% PD-L1 expression, based on the results of the KEYNOTE-24 study (#msg-123339268). Hence, such patients are not going to use first-line chemo anymore, and third-party payers won’t be able to restrict such patients to cheap generic chemo regimens. Inasmuch as Opdivo and Keytruda have similar prices, payers won’t have any particular reason to oppose (off-label) Opdivo use in first-line NSCLC.

All told, in due course I foresee Opdivo and Keytruda dividing the NSCLC market roughly evenly rather than the lopsided win for Keytruda that some investors and analysts are now predicting.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.